LOGIN  |  REGISTER
Recursion
Terns Pharmaceuticals

Elanco Animal Health to Participate in Stifel 2023 Jaws and Paws Conference

May 25, 2023 | Last Trade: US$13.79 0.11 0.80

GREENFIELD, Ind. / May 25, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Stifel 2023 Jaws and Paws Conference on Thursday, June 1, 2023. Todd Young, executive vice president and CFO, will participate in a fireside chat at 1:50 p.m. ET.

A live audio webcast will be available in the “Events and Presentations” section of Elanco’s investor website. A replay will be available for approximately 30 days.

ABOUT ELANCO

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ Sustainability/ESG framework – all to advance the health of animals, people and the planet. Learn more at www.elanco.com.

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page